1-2 of 2
Makoto Nishio
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer

Open Access
Hidetoshi Hayashi, Makoto Nishio, Hiroaki Akamatsu, Yasushi Goto, Satoru Miura, Akihiko Gemma, Ichiro Yoshino, Toshihiro Misumi, Takashi Kijima, Naoto Takase, Masaki Fujita, Sadatomo Tasaka, Atsuto Mouri, Tetsuro Kondo, Kei Takamura, Yosuke Kawashima, Kazuyoshi Imaizumi, Shunichiro Iwasawa, Shintaro Nakagawa, Tetsuya Mitsudomi
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (11): 2858–2867.
https://doi.org/10.1158/2767-9764.CRC-24-0212
Published: 01 November 2024
View articletitled, Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer
Open the PDF for Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

Open Access
Makoto Nishio, Shuji Murakami, Hisato Kawakami, Kyoichi Okishio, Motohiro Tamiya, Haruki Kobayashi, Daichi Fujimoto, Shunichi Sugawara, Toshiyuki Kozuki, Yuko Oya, Hiroki Izumi, Takayuki Shiroyama, Miyako Satouchi, Noboru Yamamoto, Shota Kaname, Daiko Matsuoka, Yohei Otake, Takao Takase, Taro Semba, Koichi Azuma
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (1): 226–235.
https://doi.org/10.1158/2767-9764.CRC-23-0313
Published: 29 January 2024
View articletitled, Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort
Open the PDF for Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort in another window
Includes: Supplementary data